Biosergen AB

Equities

BIOSGN

SE0016013460

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 10:30:45 2024-04-26 am EDT			5-day change	1st Jan Change
0.341 ^SEK	+7.91%		-15.17%	-61.25%

Apr. 09	Biosergen to Issue New Units as Compensation Under Rights Issue	MT
Mar. 27	Biosergen Raises SEK26.4 Million via Rights Issue	MT

BioStock Investor Pitch: Biosergen

March 18, 2024 at 03:16 am EDT

In the BioStock Studio, Swedish Biosergen talks about the company's vision, market plan and strategy to take its product through the first patient study and on towards a global market. Strengthened by its recent agreement with Alkem, the company intends to advance its antifungal drug candidate BSG005 further by an ongoing rights issue of SEK 40.5 million.

Watch Biosergens CEO Tine Kold Olesen present the company in the BioStock Investor Pitch:

BioStock Investor Pitch - Biosergen

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

https://news.cision.com/biosergen-ab/r/biostock-investor-pitch--biosergen,c3946919

Latest news about Biosergen AB

Biosergen to Issue New Units as Compensation Under Rights Issue	Apr. 09	MT
Biosergen Raises SEK26.4 Million via Rights Issue	Mar. 27	MT
Biosergen AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Norway's Biosergen Secures Indian Regulatory Approval for Clinical Trial of Fungal Infections Therapy	Feb. 12	MT
Biosergen AB Receives Regulatory Approval to Test Lead Candidate Bsg005 in Patients with Invasive Fungal Infection	Feb. 12	CI
Biosergen Seeks Fresh Funds from Rights Offering, Secures Loan from Major Shareholder	Jan. 31	MT
Biosergen AB Announces CEO Changes	Jan. 12	CI
Biosergen AB Announces Transition of Peder M. Andersen into A Chief Medical Officer Role	Jan. 12	CI
Biosergen Conducts A New Phase 1B Study in Patients with Invasive Fungal Infections with Its Drug Candidate Bsg005 Together with Alkem	Jan. 12	CI
Biosergen's Indian Partner Seeks Approval for Clinical Trial of Antifungal Drug Candidate	Dec. 12	MT
Biosergen AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 30	CI
Biosergen AB Announces Abstract About the Drug Candidate BSG005	23-10-23	CI
Certain Shares of Biosergen AB are subject to a Lock-Up Agreement Ending on 4-OCT-2023.	23-10-03	CI
Biosergen, Alkem Laboratories Partner to Launch Clinical Trial of Fungal Disease Treatment in India	23-09-25	MT
Alkem Laboratories Limited and Biosergen AB Enter into a Co-Development and License Agreement	23-09-25	CI
Biosergen AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Biosergen AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-31	CI
Biosergen AB Announces Lena Degling Wikingsson and Hanne Mette Dyrlie Kristensen Declines Re-Election as Board Members	23-05-31	CI
Biosergen Provides Phase 2 Clinical Development Strategy Update	23-03-29	CI
Biosergen AB announces Positive Topline Data from Phase 1 Study of Bsg005 Shows It Is Safe and Well Tolerated. It Gives Hope for A Change in the Treatment Paradigm of Patients with Invasive Fungal Infections	23-03-13	CI
Biosergen Proceeds with Phase 1 Anti-Fungal Drug Trial	23-01-16	MT
Biosergen Completes the First Multiple Ascending Dose Cohort of BSG005 Phase I Trial	23-01-16	CI
Biosergen Rises 16% on Progress of Clinical Trial for Antifungal Drug Candidate	22-12-12	MT
Biosergen AB Announcest First Volunteer Has Been Dosed in the Mad Part of the Phase I Trial of BSG005	22-12-12	CI
Biosergen AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-30	CI

Chart Biosergen AB

Duration

Period

More charts

Company Profile

Biosergen AB is a Sweden-based biotechnology company. It carries out biopharmaceutical research and development through its Subsidiary Biosergen AS from laboratory facilities in Trondheim, Norway and several other places worldwide. The Company is developing BSG005, a potentially disruptive antifungal drug which has demonstrated safety and potency advantages over competing antifungals. Biosergen initially aims BSG005 towards invasive fungal infections that claim the lives of hundreds of thousands of immune-compromised AIDS, cancer and transplant patients every year. At equal dose levels BSG005 has demonstrated a three-to-fouold potency advantage against the relevant fungal strains compared to the current standard of care, while being completely free of the kidney toxicity hampering other drugs in its class.

Sector

Biotechnology & Medical Research

Calendar

2024-05-28 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIOSERGEN AB	-61.25%	4.43M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs